Clinical Trial Update: Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sapanisertib with exemestane or fulvestrant in postmenopausal ER+/HER2- metastatic breast cancer completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)
• Sapanisertib (sapanisertib)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-01-27